Pramlintide
Treatment for Diabetes mellitus type 1
Typical Dosage: 60-120 mcg subcutaneously before each major meal
Effectiveness
65%
Safety Score
60%
Clinical Trials
38
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
60-120 mcg subcutaneously before each major meal
Time to Effect
Immediate (postprandial glucose), months for weight effects
Treatment Duration
Lifetime (as needed)
Evidence Quality
MODERATEConfidence Score
75%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$7,000
Monitoring:$100
Side Effect Mgmt:$300
Total Annual:$7,400
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$200,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$12,333
Pramlintide Outcomes
for Diabetes mellitus type 1
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+60%
Common Side Effects
Nausea
+30%
Anorexia
+15%
Severe Hypoglycemia (with insulin)
+8%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
19 completed trials for Pramlintide in Diabetes mellitus type 1
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
NCT00313183COMPLETEDPHASE2
12 participants
INTERVENTIONAL
Aurora, United States +2 more
Started: Apr 1, 2006
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
NCT00108004COMPLETEDPHASE3
400 participants
INTERVENTIONAL
Anaheim, United States +47 more
Started: Apr 1, 2003
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
NCT00107107COMPLETEDPHASE3
190 participants
INTERVENTIONAL
Tempe, United States +24 more
Started: Nov 1, 2002
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
NCT00229658COMPLETED
1.3K participants
OBSERVATIONAL
Birmingham, United States +106 more
Started: Sep 1, 2005
Evaluation of the Bioavailability of Pramlintide
NCT00042471COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Orlando, United States +3 more
Started: Jun 1, 2002
Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus
NCT00442767COMPLETEDPHASE4
8 participants
INTERVENTIONAL
The Bronx, United States
Started: Feb 1, 2007
Pramlintide in Adolescents With Type 1 Diabetes
NCT00842075COMPLETEDNA
10 participants
INTERVENTIONAL
Aurora, United States
Started: Dec 1, 2006
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
NCT00042458COMPLETEDPHASE3
296 participants
INTERVENTIONAL
Mesa, United States +32 more
Started: Apr 1, 2002
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
NCT00489645COMPLETEDNA
27 participants
INTERVENTIONAL
Started: Jan 1, 2005
Continuous Subcutaneous Infusion of Pramlintide and Insulin
NCT00291772COMPLETEDPHASE4
13 participants
INTERVENTIONAL
Houston, United States
Started: Jan 1, 2006
A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus
NCT03916640COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Neuss, Germany
Started: Jan 4, 2019
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
NCT00042601COMPLETEDPHASE2
51 participants
INTERVENTIONAL
Adelaide, Australia
Started: Jul 1, 2002
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
NCT01839370COMPLETEDNA
9 participants
INTERVENTIONAL
Charlottesville, United States
Started: Jul 1, 2013
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
NCT00206297COMPLETEDPHASE3
20 participants
INTERVENTIONAL
Houston, United States
Started: Oct 1, 2003
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
NCT02500979COMPLETEDPHASE1
34 participants
INTERVENTIONAL
Chula Vista, United States +2 more
Started: Aug 17, 2015
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
NCT01708044COMPLETEDPHASE1
32 participants
INTERVENTIONAL
Portland, United States
Started: Nov 1, 2012
A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus
NCT03512236COMPLETEDPHASE1
24 participants
INTERVENTIONAL
Neuss, Germany
Started: Apr 25, 2018
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
NCT01269047COMPLETEDPHASE4
37 participants
INTERVENTIONAL
The Bronx, United States
Started: Aug 1, 2009
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas
NCT04163874COMPLETEDNA
36 participants
INTERVENTIONAL
Montreal, Canada
Started: Feb 14, 2020
Showing 20 of 38 total trials